	US 12,339,289 B2
	Astrocyte traumatome and neurotrauma biomarkers
Ina-Beate Wanner, Topanga, CA (US); and Joseph A. Loo, Encino, CA (US)
Assigned to THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, Oakland, CA (US)
Filed by THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, Oakland, CA (US)
Filed on Jan. 6, 2022, as Appl. No. 17/647,289.
Application 17/647,289 is a division of application No. 16/716,095, filed on Dec. 16, 2019, granted, now 11,249,094.
Application 16/716,095 is a division of application No. 15/570,982, granted, now 10,557,859, issued on Feb. 11, 2020, previously published as PCT/US2016/031043, filed on May 5, 2016.
Claims priority of provisional application 62/157,389, filed on May 5, 2015.
Prior Publication US 2022/0299531 A1, Sep. 22, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. G01N 33/68 (2006.01); G01N 33/577 (2006.01)

CPC G01N 33/6896 (2013.01) [G01N 33/577 (2013.01); G01N 33/6848 (2013.01); C12Y 201/01259 (2015.07); G01N 2800/2871 (2013.01); G01N 2800/40 (2013.01); G01N 2800/52 (2013.01)]

11 Claims

1. A method of detection of progression of traumatic brain injury (TBI) in a subject and treating the subject for TBI, the method comprising:

(a) contacting a specimen of bodily fluid obtained from the subject with reagents for assaying for a marker of TBI, wherein the marker of TBI comprises aldolase C (ALDOC), or a trauma-specific break down product (BDP) of ALDOC, wherein the trauma-specific BDP of ALDOC is selected from the group consisting of a 38 kDa fragment, a 35 kDa fragment, a 30 kDa fragment, and a 23 kDa fragment;

(b) measuring the amount of the marker TBI present in the specimen as compared to a reference sample;

(c) determining the presence of an elevated amount of the marker of TBI in the specimen compared to the reference sample, thereby detecting progression of TBI in the subject; and

(d) initiating or increasing treatment for TBI when the specimen is determined to have an elevated amount of the marker of TBI relative to the reference sample.